Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02695979
  4. Details
NCT02695979 Clinical Trial

Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation

Evidence of Liver Transplantation Clinical Trial

Official title:
Changes of Macrophage Migration Inhibitory Factor and Thyroid Hormones During Liver Transplantation. Association With Graft Dysfunction

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT02695979
Other study ID # 1458/2014
Secondary ID
Status Active, not recruiting
Phase N/A
First received January 12, 2016
Last updated February 28, 2018
Start date August 2014
Est. completion date August 2019

Study information
Verified date February 2018
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.

Description:

Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 100
Est. completion date August 2019
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- End stage liver disease, chronic liver failure, orthotopic liver transplantation

Exclusion Criteria:

- Combined transplantations (liver plus kidney or lung), age under 18 y, acute liver failure

Study Design

Related Conditions & MeSH terms

  • Evidence of Liver Transplantation

Locations
Country Name City State
Austria Medical University Vienna Vienna

Sponsors (1)
Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome
Type Measure Description Time frame Safety issue
Other Acute kidney injury, outcome Acute kidney injury, outcome 48 months
Primary Macrophage Migration Inhibitory Factor in human serum, liver graft effluent and urine 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT02239991 - Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant N/A
Recruiting NCT03013634 - Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation N/A
Active, not recruiting NCT02579408 - Quantifying Steatosis in Liver Transplant Donors
Completed NCT02008097 - Clinical Benefits of B-Flow Ultrasound N/A
Completed NCT04763096 - Evaluate the Efficacy and Safety of the ADVAGRAF® Phase 4
Recruiting NCT01607788 - Prospective Liver Tumor (ProLiT) Database N/A
Recruiting NCT01766518 - The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1) Phase 4
Not yet recruiting NCT01860716 - Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant. Phase 3
Completed NCT01022476 - Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients Phase 1/Phase 2
Completed NCT01546064 - Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity N/A
Completed NCT02263703 - Immunogenicity of HPV Vaccine in Immunosuppressed Children Phase 3
Terminated NCT00473824 - Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation Phase 2
Terminated NCT00151632 - Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation Phase 3
Active, not recruiting NCT02350218 - Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION) Phase 2
Completed NCT02608606 - Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors N/A
Recruiting NCT02451046 - Usefulness of Alpha-GST in Liver Transplantation N/A
Completed NCT00177931 - Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit N/A
Completed NCT01147380 - Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation Phase 1
Terminated NCT00694408 - A Pilot Trial of Pediatric Liver Transplantation Without Steroids Phase 3
Terminated NCT00375895 - Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation Phase 3